Table 1.
Baseline and survival characteristics.
| Characteristics | Control | Cancer | Cancer subtype | |||
|---|---|---|---|---|---|---|
| SCLC | NS-Ad | NS-Sq | NS-x | |||
| Number, n | 545 | 144 | 13 | 75 | 27 | 29 |
| Males, n (%) | 266 (48.8) | 66 (45.8) | 6 (42.2) | 23 (30.7)** | 18 (66.7) | 19 (65.5) |
| Age, years | 61.9 ± 13.1 | 67.1 ± 10.6** | 67.7 ± 10.9 | 64.7 ± 10.0 | 72.8 ± 9.6** | 67.5 ± 11.4* |
| BMI, kg/m2 | 25.5 ± 4.9 | 23.6 ± 3.7** | 25.6 ± 3.6 | 23.1 ± 3.5** | 23.9 ± 3.6 | 23.5 ± 4.4* |
| CRP (mg/L) | 2.6 (0.9; 6.8) | 13.9 (3.6; 32.9)** | 5.8 (2.4; 22.8)* | 8.7 (3.1; 24.0)** | 32.5 (20.6; 48.7)** | 13.1 (4.4; 33.9)** |
| eGFR | 85 (74; 99) | 90 (79; 106)** | 86 (81; 101) | 88 (78; 103) | 91 (79; 112) | 93 (83; 108) |
| Smoking status, n (%) | ||||||
| Never | 117 (21.5) | 7 (4.6) | 0 (0.0) | 4 (5.3) | 1 (3.7) | 2 (6.9) |
| Former/current | 368 (67.5) | 131 (91.0) | 13 (100.0) | 69 (92.0) | 25 (92.6) | 24 (82.8) |
| Unknown/missing | 60 (11.0) | 6 (4.2) | 0 (0.0) | 2 (2.7) | 1 (3.7) | 3 (10.3) |
| Stage, n (%) | ||||||
| 1 | 27 (18.8) | 2 (15.4) | 17 (22.7) | 2 (4.4) | 6 (20.7) | |
| 2 | 14 (9.7) | 0 (0.0) | 7 (9.3) | 4 (14.8) | 3 (10.3) | |
| 3 | 29 (20.1) | 5 (38.5) | 6 (8.0) | 13 (48.2) | 5 (17.2) | |
| 4 | 56 (38.9) | 4 (30.8) | 35 (46.7) | 5 (18.5) | 12 (41.4) | |
| Unknown | 18 (12.5) | 2 (15.4) | 10 (13.3) | 3 (11.1) | 3 (10.3) | |
| PAPP-A, ng/mL | 1.03 (0.84; 1.27) | 1.04 (0.86; 1.36) | 1.02 (0.90; 1.54) | 1.01 (0.84; 1.26) | 1.10 (0.78; 1.43) | 1.02 (0.90; 1.26) |
| PAPP-A2, ng/mL | 0.27 (0.17; 0.39) | 0.33 (0.21; 0.56)** | 0.33 (0.22; 0.78) | 0.29 (0.20; 0.47) | 0.47 (0.24; 0.67)** | 0.34 (0.23; 0.49)* |
| Survival, days | 377 (190; 1,301) | 550 (324; 1,717) | 397 (206; 1,535) | 281 (141; 899) | 307 (157; 865) | |
| Mortality at endpoint, n (%) | 78 (14.3) | 114 (79.2) | 10 (76.9) | 59 (78.7) | 23 (85.2) | 22 (75.9) |
Baseline and survival characteristics in controls, patients with lung cancer and subtypes of lung cancer. Patients are grouped as follows; control subjects (Control), all cancer patients, (Cancer), small cell lung carcinoma (SCLC), non-small cell lung carcinoma (NSCLC), NSCLC adenocarcinoma subtype (NS-Ad), NSCLC squamous cell subtype (NS-Sq), and NSCLC other subtypes than NS-Ad and NS-Sq (NS-x). Survival refers to median survival time and comprises all cancer patients who were censored or experienced an event. Categorical variables are indicated as number (n) and percentage (%) of patients, and continuous variables are mean ± SD or median (25th percentile; 75th percentile).
p < 0.05,
p < 0.005 as compared to controls.
BMI, body mass index; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; PAPP-A, pregnancy-associated plasma protein-A.